Oxford Biomedica’s long-running alliance with Sanofi over a pair of gene therapies for ophthalmic diseases has come to an end, after an internal review by the French drugmaker.
President Donald Trump’s Operation Warp Speed, which aims to make a coronavirus vaccine widely available by year-end, has come up with a shortlist of candidates, with some nota
Sanofi’s new multiple myeloma drug Sarclisa (isatuximab) has been approved in the EU for relapsed/refractory disease, taking on Johnson & Johnson’s well-established blockbuster Darzalex
Sanofi's new CEO Paul Hudson has completed his revamp of the company’s executive committee, including the appointment of a dedicated chief digital officer.
Sanofi and Regeneron’s once close relationship has been become a little more distant over the last couple of years, and the process continued this week after Sanofi said it wil
Sanofi’s CEO Paul Hudson has courted controversy by saying the French pharma’s potential COVID-19 vaccine will likely be delivered to the US government first should it succeed in clinical t